145 related articles for article (PubMed ID: 19203531)
1. Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Boeckmann L; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Struever D; Emmert S
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):33-5. PubMed ID: 19203531
[No Abstract] [Full Text] [Related]
2. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
[TBL] [Abstract][Full Text] [Related]
3. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
[TBL] [Abstract][Full Text] [Related]
6. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.
Su Y; Yin L; Liu R; Sheng J; Yang M; Wang Y; Pan E; Guo W; Pu Y; Zhang J; Liang G
Med Oncol; 2014 Feb; 31(2):784. PubMed ID: 24366688
[TBL] [Abstract][Full Text] [Related]
8. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
[TBL] [Abstract][Full Text] [Related]
9. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Calegari MA; Inno A; Monterisi S; Orlandi A; Santini D; Basso M; Cassano A; Martini M; Cenci T; de Pascalis I; Camarda F; Barbaro B; Larocca LM; Gori S; Tonini G; Barone C
Br J Cancer; 2017 May; 116(10):1279-1286. PubMed ID: 28427088
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
13. MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Erice O; Smith MP; White R; Goicoechea I; Barriuso J; Jones C; Margison GP; Acosta JC; Wellbrock C; Arozarena I
Mol Cancer Ther; 2015 May; 14(5):1236-46. PubMed ID: 25777962
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
16. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
17. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Eich M; Roos WP; Nikolova T; Kaina B
Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
[TBL] [Abstract][Full Text] [Related]
18. MGMT methylation in glioblastoma: tale of the tail.
Shah N; Schroeder B; Cobbs C
Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
[No Abstract] [Full Text] [Related]
19. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
20. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
